A Clinical Study Of The Effect Of Deanxit On Improving Heart Function In Patients With Chronic Heart Failure Combined With Anxiety And Depression After Myocardial Infarction

Objective:1、To explore the effect of Deanxit on clinical symptoms of anxiety and depression, Cardiac function parameters in patients with chronic heart failure after myocardial infarction(MI).2、To explore the effects of Deanxit on the level of endothelin-1(ET-1),human plasminogen activator inhibitor-1(PAI-1)and angiotensin Ⅱ(AngⅡ)of patients after myocardial infarction(MI).Methods:Total 80 patients with chronic heart failure combined anxiety and depression after MI were randomly divided into experimental group and control group(n=40,respectively). The control group was provided with conventional treatments for heart failure,(including nitrates, angiotensinconverting enzyme inhibitors, anticoagulants, statins, digitalis, and diuretics),while the experimental group was provided with Deanxit in addition to conventional treatments. Treatment efficacy was evaluated with Hamilton Anxiety Scale(HAMA) score and Hamilton Depression Scale(HAMD) score before treatment and after 2-weeks treatment. Changes in NYHA classification and the stroke volume(SV), cardiac output(CO), and ejection fraction(EF) were also examined. Serum levels of endothelin-1(ET-1),human plasminogen activator inhibitor-1(PAI-1) and angiotensin Ⅱ(AngⅡ) were measured as well.Results:1、The difference of the total efficacy rate in improving NYHA heart functional class between the experimental group(95.00%) and control group(75.00%) was statistically significant(P<0.05).2、After 2-weeks treatment,the scores of HAMA and HAMD have some decrease in both groups, but the scores of HAMA and HAMD after treatment in experimental group were significantly lower than those of the control group( HAMA : 9.31±4.82 vs 13.26±7.84, P<0.01; HAMD :10.91±2.82 vs 16.31±3.81,P<0.01).3、The levels of serum endothelin-1(ET-1), serum human plasminogen activator inhibitor-1(PAI-1) and serum angiotensin Ⅱ(AngⅡ) of both groups after 2-weeks’ treatment have some decrease compared with that before treatment, but after 2-weeks’ treatment the levels of serum endothelin-1(ET-1), of human plasminogen activator inhibitor-1(PAI-1) and of angiotensinⅡ(AngⅡ) were significantly lower in the experimental group than that in the control group(ET-1:102.36±7.32 ng/ml vs 125.32±7.36 ng/ml,P<0.01;PAI-1:65.02±5.98 pg/ml vs 76.78±7.02 pg/ml,P<0.01;AngⅡ:15.98±1.69pg/ml vs 20.78±2.93 pg/ml; P<0.01).4 、 After 2-weeks’ treatment, the SV, CO and LVEF of both groups patients have some degree improvement,but the SV, CO and LVEF of the experimental group were significantly higher than those of control group(SV:92.36±32.25 ml/s vs 85.22±14.56 ml/s,P<0.01;CO:7.89±3.45 L/min vs 6.38±2.98 L/min, P<0.05;EF:55.98±12.78% vs 46.32±10.72%,P<0.01).Conclusion:Deanxit can effectively improve the clinical symptoms of patients with heart failure combined with anxiety and depression after MI, reduce the levels of ET-1, PAI-1, and AngⅡof the patients, and improve the heart function.